GlassScriptPhysician profile
Krisha Patel
NPI 1073081725
$2,032.38
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,748 · 2022: $131 · 2023: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $153.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $404.84 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $302.69 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $224.66 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $135.95 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $121.90 | 2021-2023 | |
| Jazz Pharmaceuticals INC. | $111.70 | 2021 | |
| Bausch Health US, LLC | $82.68 | 2021 | |
| Avanir Pharmaceuticals, INC. | $72.44 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $65.67 | 2021 | |
| Vanda Pharmaceuticals INC. | $61.80 | 2021 | |
| Neos Therapeutics, LP | $54.26 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $48.47 | 2021 | |
| Medtronic, INC. | $40.40 | 2023 | Interstim |
| Arbor Pharmaceuticals, INC. | $28.32 | 2021 | |
| Adlon Therapeutics L.P. | $28.16 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $23.05 | 2021 | |
| Sumitomo Pharma America, INC. | $21.85 | 2023 | Gemtesa |
| Blue Earth Diagnostics | $20.67 | 2022 | |
| Tolmar, INC. | $20.66 | 2023 | |
| Pfizer INC. | $20.55 | 2021 | |
| Lundbeck LLC | $20.40 | 2021 | |
| Urovant Sciences INC | $19.27 | 2022 | |
| Urogen Pharma, INC. | $19.00 | 2022 | |
| Alfasigma USA, INC. | $18.35 | 2021 | |
| Abbvie INC. | $17.29 | 2021 | |
| Eisai INC. | $17.08 | 2021 | |
| Mission Pharmacal Company | $16.18 | 2023 | Uribel |
| Agios Pharmaceuticals, INC. | $14.09 | 2023 | Pyrukynd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krisha Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.